The DOI matches its Crossref record; 52 of the 55 references it cites were found in a registry or an index.
Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends
Abstract
Context Bladder cancer has become a common cancer globally, with an estimated 430 000 new cases diagnosed in 2012. Objective We examine the most recent global bladder cancer incidence and mortality patterns and trends, the current understanding of the aetiology of the disease, and specific issues that may influence the registration and reporting of bladder cancer. Evidence acquisition Global bladder cancer incidence and mortality statistics are based on data from the International Agency for Research on Cancer and the World Health Organisation (Cancer Incidence in Five Continents, GLOBOCAN, and the World Health Organisation Mortality). Evidence synthesis Bladder cancer ranks as the ninth most frequently-diagnosed cancer worldwide, with the highest incidence rates observed in men in Southern and Western Europe, North America, as well in certain countries in Northern Africa or Western Asia. Incidence rates are consistently lower in women than men, although sex differences varied greatly between countries. Diverging incidence trends were also observed by sex in many countries, with stabilising or declining rates in men but some increasing trends seen for women. Bladder cancer ranks 13th in terms of deaths ranks, with mortality rates decreasing particularly in the most developed countries; the exceptions are countries undergoing rapid economic transition, including in Central and South America, some central, southern, and eastern European countries, and the Baltic countries. Conclusions The observed patterns and trends of bladder cancer incidence worldwide appear to reflect the prevalence of tobacco smoking, although infection with Schistosoma haematobium and other risk factors are major causes in selected populations. Differences in coding and registration practices need to be considered when comparing bladder cancer statistics geographically or over time. Patient summary The main risk factor for bladder cancer is tobacco smoking. The observed patterns and trends of bladder cancer incidence worldwide appear to reflect the prevalence of tobacco smoking.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The epidemiology of bladder cancer varies by region, with tobacco smoking, occupational exposures (e.g., aromatic amines), and arsenic contamination of drinking water among the putative causes in industrialized countries.159,160”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [160]
In the citing paper
“Diverging bladder cancer incidence trends have been observed by sex since the 1990s, with rates tending to decrease or stabilize in men but increase among women in certain European countries (e.g., in Spain, the Netherlands, Germany, and Belarus).160,162,163”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [160]
In the citing paper
“comparing trends in bladder cancer mortality rates may be more suitable for assessing progress in disease control.160,166”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [160]
In the citing paper
“Of note, there may be artifactual changes in incidence because of differences in coding and registration practice concerning inclusion or otherwise of noninvasive carcinomas.160,166,167”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [160]
In the citing paper
“increases in mortality rates have also been reported among men in Thailand, Israel, and Slovakia and among women in Thailand, Japan, Croatia, and Poland.160”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [160]
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Self-citationCancer Incidence in Five Continents
Doll, R., Muir, C. S., & Waterhouse, J. A. H. (1970) · Springer eBooks · doi:10.1007/978-3-642-85851-2 · Cited by 8,485
The United Nations Development Programme
Oestreich, J. E. (2017) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780190637347.003.0003 · Cited by 4,875
The global health burden of infection‐associated cancers in the year 2002
Parkin, D. M. (2006) · International Journal of Cancer · doi:10.1002/ijc.21731 · Cited by 2,932
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016
Babjuk, M. M., Andreas Böhle, E., Burger, M., Čapoun, O., Cohen, D. L., Compérat, É., Hernández, V., KAASINEN, E. S., Palou, J., Morgan Rouprêt, A., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.05.041 · Cited by 2,240
Epidemiology and Risk Factors of Urothelial Bladder Cancer
Burger, M., Catto, J. W. F., Dalbagni, G. M., Grossman, H. B., Herr, H. W., Karakiewicz, P. I., Kassouf, W., Kiemeney, L. A. L. M., Vecchia, C. L., Shariat, S. F., et al. (2012) · European Urology · doi:10.1016/j.eururo.2012.07.033 · Cited by 2,212
Steinmann, P., Keiser, J., Bos, R., Tanner, M., & Utzinger, J. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70521-7 · Cited by 2,146
Smoking prevalence and cigarette consumption in 187 countries, 1980-2012
Ng, M., Freeman, M. K., Fleming, T. D., Robinson, M., Dwyer-Lindgren, L., Thomson, B., Wollum, A., Sanman, E., Wulf, S., Lopez, A. D., et al. (2014) · JAMA · doi:10.1001/jama.2013.284692 · Cited by 1,576
Estimating average annual per cent change in trend analysis
Clegg, L. X., Hankey, B. F., Tiwari, R. C., Feuer, E. J., & Edwards, B. K. (2009) · Statistics in Medicine · doi:10.1002/sim.3733 · Cited by 1,271
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013
Babjuk, M., Burger, M., Zigeuner, R., Shariat, S. F., van Rhijn, B. W. G., Compérat, E., Sylvester, R. J., Kaasinen, E., Böhle, A., Palou Redorta, J., et al. (2013) · European Urology · doi:10.1016/j.eururo.2013.06.003 · Cited by 1,174
Research works printed but not linked: 1
- Loader C. Smoothing: Local Regression Techniques Web site. http://hdl.handle.net/10419/22186.
Cited by
Sorted by citations
Items 301–400 of 1,000
Hope and challenge: Precision medicine in bladder cancer
Su, H., Jiang, Q., Tao, T., Kang, X., Zhang, X., Kang, D., Li, S., Li, C., Wang, H., Yang, Z., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.1979 · Cited by 46
Li, F., Yang, C., Zhang, H., Ma, J., Jia, J., Tang, X., Zeng, J., Chong, T., Wang, X., He, D., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2385 · Cited by 46
Gatta, L. B., Melocchi, L., Bugatti, M., Missale, F., Lonardi, S., Zanetti, B., Cristinelli, L., Belotti, S., Simeone, C., Ronca, R., et al. (2019) · Cancers · doi:10.3390/cancers11091219 · Cited by 46
Circular RNA circRGNEF promotes bladder cancer progression via miR-548/KIF2C axis regulation
Yang, C., Li, Q., Chen, X., Zhang, Z., Mou, Z., Ye, F., Jin, S., Jun, X., Tang, F., & Jiang, H. (2020) · Aging · doi:10.18632/aging.103047 · Cited by 46
Laamari, Y., Oubella, A., Bimoussa, A., Mansouri, A. E., Ketatni, E. M., Mentré, O., Itto, M. Y. A., Morjani, H., Khouili, M., & Auhmani, A. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105165 · Cited by 45
EIF4A3-mediated biogenesis of circSTX6 promotes bladder cancer metastasis and cisplatin resistance
Wei, W., Liu, K., Huang, X., Tian, S., Wang, H., Zhang, C., Ye, J., Dong, Y., An, Z., Ma, X., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02932-6 · Cited by 47
Qiu, J., Cheng, Z., Jiang, Z., Gan, L., Zhang, Z., & Xie, Z. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105490 · Cited by 53
Li, J., Kong, Z., Qi, Y., Wang, W., Su, Q., Huang, W., Zhang, Z., Li, S., & Du, E. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001516 · Cited by 46
Søgaard, C. K., Blindheim, A., Røst, L. M., Petrović, V., Nepal, A., Bachke, S., Liabakk, N., Gederaas, O. A., Viset, T., Arum, C., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25963 · Cited by 45
Secondhand smoking increases bladder cancer risk in nonsmoking population: a meta-analysis
Yan, H., Ying, Y., Xie, H., Li, J., Wang, X., He, L., Jin, K., Tang, J., Xu, X., & Zheng, X. (2018) · Cancer Management and Research · doi:10.2147/cmar.s175062 · Cited by 45
Inhibition of autophagy enhances the anticancer effect of enzalutamide on bladder cancer
Quan, Y., Lei, H., Wahafu, W., Liu, Y., Ping, H., & Zhang, X. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109490 · Cited by 45
Temporal trends of kidney cancer incidence and mortality from 1990 to 2016 and projections to 2030
Cai, Q., Chen, Y., Qi, X., Zhang, D., Pan, J., Xie, Z., Xu, C., Li, S., Zhang, X., Gao, Y., et al. (2020) · Translational Andrology and Urology · doi:10.21037/tau.2020.02.23 · Cited by 43
Miranda, M. A., Silva, L. B., Carvalho, I. P. S., do Amaral, R. L. F., de Paula, M. H., Swiech, K., Bastos, J. K., Paschoal, J. A. R., Emery, F. D. S., dos Reis, R. B., et al. (2020) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2020.111106 · Cited by 45
Arita, Y., Shigeta, K., Akita, H., Suzuki, T., Kufukihara, R., Kwee, T. C., Ishii, R., Mikami, S., Okuda, S., Kikuchi, E., et al. (2020) · European Radiology · doi:10.1007/s00330-020-07153-5 · Cited by 45
Current status and future perspectives of immunotherapy in bladder cancer treatment
Wu, Z., Liu, J., Dai, R., & Wu, S. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1768-y · Cited by 45
Moussa, F. B., Achi, F., Meskher, H., Henni, A., & Belkhalfa, H. (2022) · Materials Chemistry and Physics · doi:10.1016/j.matchemphys.2022.126456 · Cited by 45
An eight-long non-coding RNA signature as a candidate prognostic biomarker for bladder cancer
Lian, P., Wang, Q., Zhao, Y., Chen, C., Sun, X., Li, H., Deng, J., Zhang, H., Ji, Z., Zhang, X., et al. (2019) · Aging · doi:10.18632/aging.102225 · Cited by 44
Wang, C., Tao, W., Ni, S., & Chen, Q.-Y. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s215823 · Cited by 44
RetractedDeng, X., Huang, Y., Zhang, J., Chen, Y., Jiang, F., Zhang, Z., Li, T., Hou, L., Tan, W., & Li, F. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114119 · Cited by 49
Luo, H. R., Yang, R., Li, C., Tong, Y., Fan, L., Liu, X., & Xu, C. (2017) · Tumor Biology · doi:10.1177/1010428317718414 · Cited by 44
Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer
Katz, H., Wassie, E. A., & Alsharedi, M. F. (2017) · Medical Oncology · doi:10.1007/s12032-017-1029-8 · Cited by 44
Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines
Skowron, M. A., Melnikova, M., van Roermund, J. G. H., Romano, A., Albers, P., Thomale, J., Schulz, W. A., Niegisch, G., & Hoffmann, M. J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020590 · Cited by 44
Graphene-based nanomaterials in cancer treatment and diagnosis
Eskiizmir, G., Baskın, Y., & Yapıcı, K. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813691-1.00009-9 · Cited by 44
Tardivon, C., Desmée, S., Kerioui, M., Bruno, R., Wu, B. M., Mentré, F., Mercier, F., & Guedj, J. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1450 · Cited by 44
Lee, Y., & Tuyet, P.-T. (2019) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-019-00363-2 · Cited by 45
Nunzio, C. D., Cicione, A. M., Izquierdo, L., Lombardo, R., Tema, G., Lotrecchiano, G., Minervini, A., Simone, G., Cindolo, L., D’Orta, C., et al. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.07.002 · Cited by 44
Microbe–MUC1 Crosstalk in Cancer-Associated Infections
Bose, M., & Mukherjee, P. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.10.003 · Cited by 44
Papadimitriou, M., Avgeris, M., Levis, P. K., Papasotiriou, E. C., Kotronopoulos, G., STRAVODIMOS, K. G., & Scorilas, A. (2020) · Cancers · doi:10.3390/cancers12123661 · Cited by 44
Mushtaq, J., Thurairaja, R., & Nair, R. (2019) · Surgery (Oxford) · doi:10.1016/j.mpsur.2019.07.003 · Cited by 44
Retracted: LncRNA AWPPH inhibits SMAD4 via EZH2 to regulate bladder cancer progression
Zhu, F., Zhang, X., Yu, Q., Han, G., Diao, F., Wu, C., & Zhang, Y. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26556 · Cited by 43
RetractedKong, D., Chen, F., & Sima, N. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s122463 · Cited by 43
The molecular limitations of biomarker research in bladder cancer
Vlachostergios, P. J., & Faltas, B. M. (2018) · World Journal of Urology · doi:10.1007/s00345-018-2462-9 · Cited by 44
Wang, F., Wu, D., Xu, Z., Chen, J., Zhang, J., Li, X., Chen, S., He, F., Xu, J., Su, L., et al. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0758-5 · Cited by 43
En bloc resection for nonmuscle invasive bladder cancer
Mori, K., D’Andrea, D., Enikeev, D. V., Egawa, S., & Shariat, S. F. (2019) · Current Opinion in Urology · doi:10.1097/mou.0000000000000697 · Cited by 43
Sharma, P., Sohn, J., Shin, S. J., Oh, D., Keam, B., Lee, H. J., Gizzi, M., Kalinka‐Warzocha, E., Vos, F. D., Ruscica, D., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1635 · Cited by 45
Recent cancer incidence trends in Ukraine and short-term predictions to 2022
Ryzhov, A., Bray, F., Ferlay, J., Zp, F., Goulak, L., Gorokh, Y., Sumkina, O. V., Michailovich, Y., & Znaor, A. (2019) · Cancer Epidemiology · doi:10.1016/j.canep.2019.101663 · Cited by 46
Self-citationWu, Z., Wang, M.-R., Liu, Q., Liu, Y., Zhu, K., Chen, L., Guo, H., Li, Y., & Shi, B. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.39056 · Cited by 43
Mortality Trends from Urologic Cancers in Europe over the Period 1980–2017 and a Projection to 2025
Bertuccio, P., Santucci, C., Carioli, G., Malvezzi, M., Vecchia, C. L., & Negri, E. (2021) · European Urology Oncology · doi:10.1016/j.euo.2021.05.005 · Cited by 42
DNA polymerase POLD1 promotes proliferation and metastasis of bladder cancer by stabilizing MYC
Wang, Y., Ju, L., Wang, G., Qian, K., Jin, W., Li, M., Yu, J., Shi, Y., Wang, Y., Zhang, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38160-x · Cited by 41
Lifestyle and nutritional modifiable factors in the prevention and treatment of bladder cancer
Kwan, M. L., Garren, B., Nielsen, M. E., & Tang, L. (2018) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2018.03.019 · Cited by 42
Targeting DNA Methyltranferases in Urological Tumors
Marques-Magalhães, Â., Graça, I. C. R., Henrique, R., & Jerónimo, C. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00366 · Cited by 43
Heide, T., Maurer, A., Eipel, M., Knoll, K., Geelvink, M., Veeck, J., Knuechel, R., van Essen, J., Stoehr, R., Hartmann, A., et al. (2019) · The Journal of Pathology · doi:10.1002/path.5250 · Cited by 41
Chen, J., Chou, F.-J., Yeh, S., Ou, Z., Shyr, C., Huang, C., Xiang, Z., Sun, Y., Messing, E. M., Zu, X., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0964-6 · Cited by 42
Tao, K., Liu, S., Wang, L., Qiu, H., Li, B., Zhang, M., Guo, M., Liu, H., Zhang, X., Liu, Y., et al. (2019) · Biomaterials Science · doi:10.1039/c9bm01377f · Cited by 42
Bladder cancer survival nomogram
Zhang, Y., Hong, Y., Zhuang, D.-W., He, X., & Lin, M. (2019) · Medicine · doi:10.1097/md.0000000000017725 · Cited by 42
Zhan, Y., Zhang, L., Yu, S., Wen, J., Liu, Y., & Zhang, X. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01624-9 · Cited by 42
Smoking and bladder cancer: review of the recent literature
Mori, K., Mostafaei, H., Abufaraj, M. M., Yang, L., Egawa, S., & Shariat, S. F. (2020) · Current Opinion in Urology · doi:10.1097/mou.0000000000000804 · Cited by 42
Expression profile of microRNAs in bladder cancer and their application as biomarkers
Taheri, M. N., Shirvani-Farsani, Z., Ghafouri‐Fard, S., & Omrani, M. D. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110703 · Cited by 42
Xiao, M., Liu, J., Xiang, L., Zhao, K., He, D., Zeng, Q., Zhang, Q., Xie, D., Deng, M., Zhu, Y., et al. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.241 · Cited by 40
Morphological and mechanical changes induced by quercetin in human T24 bladder cancer cells
Adami, B. S., Diz, F. M., Oliveira Gonçalves, G. P., Reghelin, C. K., Scherer, M., Dutra, A. P., Papaléo, R. M., de Oliveira, J. R., Morrone, F. B., Wieck, A., et al. (2021) · Micron · doi:10.1016/j.micron.2021.103152 · Cited by 42
Ferro, M., Tătaru, O. S., Musi, G., Lucarelli, G. T., Farhan, A. R. A., Cantiello, F., Damiano, R., Hurle, R. F., Contieri, R., Busetto, G. M., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12030586 · Cited by 42
Luo, L., Miao, P., Ming, Y., Tao, J., & Shen, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.596623 · Cited by 39
Identification of the Functions and Prognostic Values of RNA Binding Proteins in Bladder Cancer
Wu, Y., Liu, Z., Wei, X., Feng, H., Hu, B., Liu, B., Luan, Y., Ruan, Y., Liu, X., Liu, Z., et al. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.574196 · Cited by 40
Opium alkaloids, biosynthesis, pharmacology and association with cancer occurrence
Vadhel, A., Bashir, S., Mir, A. H., Girdhar, M., Kumar, D., Kumar, A., Mohan, A., Malik, T., & Mohan, A. (2023) · Open Biology · doi:10.1098/rsob.220355 · Cited by 41
Mild magnetic hyperthermia-activated immuno-responses for primary bladder cancer therapy
Qi, F., Bao, Q., Hu, P., Guo, Y., Yang, Y., Yao, X., & Shi, J. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122514 · Cited by 42
Association of smoking status with prognosis in bladder cancer: A meta-analysis
Hou, L., Hong, X., Dai, M., Chen, P., Zhao, H., Wei, Q., Li, F., & Tan, W. (2016) · Oncotarget · doi:10.18632/oncotarget.13606 · Cited by 41
Wu, S., Huang, J., Liu, Z., Chen, H., Guo, P., Cai, Q., Zheng, J., Qin, H.-D., Zheng, Z., Chen, X., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.03.034 · Cited by 41
Muscle-invasive bladder cancer organ-preserving therapy: systematic review and meta-analysis
García‐Perdomo, H. A., Montes-Cardona, C. E., Guachetá-Bomba, J. M., Castillo, D. F., & Reis, L. O. (2018) · World Journal of Urology · doi:10.1007/s00345-018-2384-6 · Cited by 41
Adeloye, D., Harhay, M. O., Ayepola, O. O., Santos, J. P. D., David, R. A., Ogunlana, O. O., Gadanya, M. A., Osamor, V. C., Amuta, A. O., Iweala, E., et al. (2018) · International Journal of Urology · doi:10.1111/iju.13824 · Cited by 41
Mori, K., Miura, N., Mostafaei, H., Quhal, F., Motlagh, R. S., Lysenko, I., Kimura, S., Egawa, S., Karakiewicz, P. I., & Shariat, S. F. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01690-1 · Cited by 41
Yu, E. Y.-W., Wesselius, A., Mehrkanoon, S., Brinkman, M. T., van den Brandt, P. A., White, E., Weiderpass, E., Calvez‐Kelm, F. L., Gunter, M. J., Huybrechts, I., et al. (2020) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqaa215 · Cited by 44
EGCG Enhanced the Anti-tumor Effect of Doxorubicine in Bladder Cancer via NF-κB/MDM2/p53 Pathway
Luo, K.-W., Zhu, X., Zhao, T., Zhong, J., Gao, H., Luo, X., & Huang, W. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.606123 · Cited by 41
Rahman, Z., Bazaz, M. R., Devabattula, G., Khan, M. A., & Godugu, C. (2020) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22674 · Cited by 40
Liu, Y., Wang, R., Hou, J., Sun, B., Zhu, B., Qiao, Z., Su, Y., & Zhu, X. (2018) · ACS Applied Bio Materials · doi:10.1021/acsabm.8b00501 · Cited by 40
Anti-tumor activity and mechanistic characterization of APE1/Ref-1 inhibitors in bladder cancer
Fishel, M., Xia, H., McGeown, J., McIlwain, D. W., Elbanna, M., Craft, A. A., Kaimakliotis, H. Z., Sandusky, G., Zhang, C., Pili, R., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1166 · Cited by 37
Design of high stability thin-film transistor biosensor for the diagnosis of bladder cancer
Li, Y., Zeng, B., Yang, Y., Liang, H., Yang, Y., & Yuan, Q. (2020) · Chinese Chemical Letters · doi:10.1016/j.cclet.2020.03.043 · Cited by 40
Niu, W., Xu, L., Li, J., Zhai, Y., Sun, Z., Shi, W., Jiang, Y., Ma, C., Lin, H., Guo, Y., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.11839 · Cited by 41
Targeting Stat3 signaling impairs the progression of bladder cancer in a mouse model.
Korac-Prlic, J., Degoricija, M., Vilović, K., Haupt, B., Ivanišević, T., Franković, L., Grivennikov, S., & Terzic, J. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.06.018 · Cited by 36
Lyu, Q., Lin, A., Cao, M., Xu, X., Luo, P., & Zhang, J. (2020) · Cancer Control · doi:10.1177/1073274820976665 · Cited by 42
Gypenoside‐Induced Apoptosis via the PI3K/AKT/mTOR Signaling Pathway in Bladder Cancer
Li, X., Liu, H., Lv, C., Du, J., Lian, F., Zhang, S., Wang, Z., & Zeng, Y. (2022) · BioMed Research International · doi:10.1155/2022/9304552 · Cited by 40
Temporal trends of bladder cancer incidence and mortality from 1990 to 2016 and projections to 2030
Cai, Q., Chen, Y., Xin, S., Zhang, D., Pan, J., Xie, Z., Xu, C., Li, S., Zhang, X., Gao, Y., et al. (2020) · Translational Andrology and Urology · doi:10.21037/tau.2020.02.24 · Cited by 38
Jin, M., Lu, S., Wu, Y., Yang, C., Shi, C., Wang, Y., & Huang, G. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01697-6 · Cited by 39
RetractedLiquid Biopsy: Current advancements in clinical practice for bladder cancer
Crocetto, F., Amicuzi, U., Musone, M., Magliocchetti, M., Lieto, D. D., Tammaro, S., Pastore, A. L., Fuschi, A., Falabella, R., Ferro, M., et al. (2025) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2025.100310 · Cited by 39
ZFAS1 functions as an oncogenic long non-coding RNA in bladder cancer
Yang, H., Li, G., Cheng, B., & Jiang, R. (2018) · Bioscience Reports · doi:10.1042/bsr20180475 · Cited by 39
Bovenkamp, D., Sentosa, R., Rank, E. A., Erkkilä, M. T., Placzek, F., Püls, J., Drexler, W., Leitgeb, R. A., Garstka, N., Shariat, S. F., et al. (2018) · Applied Sciences · doi:10.3390/app8122371 · Cited by 39
Chen, S., Zhou, Q., Guo, Z., Wang, Y., Wang, L., Liu, X., Lü, M., Ju, L., Xiao, Y., & Wang, X. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14878 · Cited by 37
Xing, Y., Chen, L., Gu, H., Yang, C., Zhao, J., Chen, Z., Xiong, M., Kazobinka, G., Liu, Y., & Hou, T. (2021) · Oncogene · doi:10.1038/s41388-021-01693-w · Cited by 39
Wang, X., He, H., Rui, W., Zhang, N., Zhu, Y., & Xie, X. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03173-x · Cited by 39
Bladder resident macrophages: Mucosal sentinels
Mariano, L. L., & Ingersoll, M. A. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.01.018 · Cited by 38
Methods for bladder cancer diagnosis – The role of autofluorescence and photodynamic diagnosis
Bochenek, K., Aebisher, D., Międzybrodzka, A., Cieślar, G., & Kawczyk‐Krupka, A. (2019) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2019.05.036 · Cited by 38
Cordero, E., Rüger, J., Marti, D., Mondol, A. S., Hasselager, T., Mogensen, K., Hermann, G. G., Popp, J., & Schie, I. W. (2019) · Journal of Biophotonics · doi:10.1002/jbio.201960025 · Cited by 38
Ningchuan, S., Liang, Y., Chen, Y., Wang, L., Li, D., Liang, Z., Sun, L., Wang, Y., & Niu, H. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4385 · Cited by 38
Yin, X., Zheng, X., Liu, M., Wang, D., Sun, H., Qiu, Y., Chen, J., & Shi, B. (2019) · Cell Biology International · doi:10.1002/cbin.11292 · Cited by 38
Zhu, G., Wang, K., Qin, H., Zhao, X., Chen, W., Xu, L., Cao, W., & Guo, H. (2020) · Journal of Nanobiotechnology · doi:10.1186/s12951-020-00686-3 · Cited by 38
Wetteland, R., Engan, K., Eftestøl, T., Kvikstad, V., & Janssen, E. A. M. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820946787 · Cited by 38
Sharma, S., & Basu, B. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121331 · Cited by 38
The Role of Keratin17 in Human Tumours
Zhang, H., Zhang, Y., Xia, T., Lu, L., Luo, M., Chen, Y., Liu, Y., & Li, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.818416 · Cited by 38
Yi, R., Hong, S., Zhang, Y., Lin, A., Ying, H., Zou, W., Wang, Q., Wei, T., Cheng, Q., Zhu, W., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.757137 · Cited by 37
Demir, R., Koc, S., Öztürk, D. G., Bilir, Ş., Özata, İ. H., Williams, R., Christy, J., Akkoç, Y., Tınay, İ., Gündüz-Demir, Ç., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-52728-7 · Cited by 37
Urological cancer statistics on incidence from 1975 to 2019 and mortality from 1958 to 2022 in Japan
Sasaki, T., Higashi, T., & Inoue, T. (2024) · International Journal of Clinical Oncology · doi:10.1007/s10147-024-02575-3 · Cited by 37
Urinary cell-free nucleic acid IQGAP3: a new non-invasive diagnostic marker for bladder cancer
Kim, W. T., Kim, Y. H., Jeong, P., Seo, S.-P., Kang, H.-W., Kim, Y., Yun, S. J., Lee, G. T., Moon, S.-K., Choi, Y.-H., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24436 · Cited by 37
Stangl‐Kremser, J., D’Andrea, D., Vartolomei, M. D., Abufaraj, M. M., Goldner, G. M., Baltzer, P., Shariat, S. F., & Tamandl, D. (2018) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2018.11.001 · Cited by 38
High TNFAIP6 level is associated with poor prognosis of urothelial carcinomas
Chan, T., Li, C., Ke, H., Wei, Y., Shiue, Y.-L., Li, C., Yeh, H., Lee, H.-Y., Huang, S.-K., Wu, W., et al. (2018) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2018.12.009 · Cited by 37
The identification of new biomarkers for bladder cancer: A study based on TCGA and GEO datasets
Hu, J., Zhou, L., Song, Z., Xiong, M., Zhang, Y., Yang, Y., Chen, K., & Chen, Z. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28208 · Cited by 37
The interaction of gender and smoking on bladder cancer risks
Janisch, F., Shariat, S. F., Schernhammer, E. S., Rink, M., & Fajković, H. (2019) · Current Opinion in Urology · doi:10.1097/mou.0000000000000602 · Cited by 37
Role of tyrosine kinases in bladder cancer progression: an overview
Zangouei, A. S., Barjasteh, A. H., Rahimi, H. R., Mojarrad, M., & Moghbeli, M. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00625-7 · Cited by 37
Bosetti, C., Traini, E., Alam, S., Allen, C. A., Carreras, G., Compton, K., Fitzmaurice, C., Force, L. M., Gallus, S., Gorini, G., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-79176-3 · Cited by 37
Wnt signalling pathway in bladder cancer
Wu, G., Weng, W., Xia, P., Yan, S., Zhong, C., Xie, L., Xie, Y., & Fan, G. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109886 · Cited by 36
Zheng, Y., Zhang, W., Xu, L., Zhou, H., Yuan, M., & Xu, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.795548 · Cited by 37
Wen, W., Li, J., Wang, L., Xing, Y., Li, X., Ruan, H., Xi, X., Xiong, J., & Kuang, R. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1338220 · Cited by 36
Metadata
- Authors
- Antoni, S., Ferlay, J., Soerjomataram, I., Znaor, A., Jemal, A., & Bray, F.
- Affiliations
- Centre international de recherche sur le cancer (FR)
- American Cancer Society (US)
- Corresponding author
- Bray, Freddie
- Venue
- European Urology
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 71
- Issue
- 1
- Pages
- 96-108
- ISSN
- 0302-2838 (ISSN-L)
- OpenAlex
- W2473162054
- Cited by
- 2,514
- References
- 55
- Citations by year
- 2026: 79 · 2025: 165 · 2024: 248 · 2023: 244 · 2022: 314 · 2021: 414 · 2020: 400 · 2019: 306 · 2018: 225 · 2017: 102
- FWCI
- 21.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Urology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- World Health Organization
- Topics
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Health Sciences › Medicine › Surgery › Urinary and Genital Oncology Studies
- Keywords
- bladder cancer, cancer incidence, cancer mortality, incidence trends, sex differences, smoking, Schistosoma haematobium, etiology, global cancer statistics
- MeSH terms
- Urinary Bladder Neoplasms, Female, Humans, Male, Registries, Risk Factors, Smoking, Global Health, Incidence, Internationality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
